Introduction: The aim of this analysis was to describe in real-world settings the clinical
INTRODUCTION
Patients with profound and prolonged neutropenia are at a major risk of infection [1] .
Febrile neutropenia is generally a complication of myelosuppressive chemotherapy and requires immediate evaluation to avoid progression to a sepsis syndrome and possibly death [2, 3] . Gram-positive bacteria are currently the leading agents responsible for infections in patients with neutropenia worldwide [4] . Moreover, a major concern is that resistant
Gram-positive pathogens, such as methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE), have become common in these patients. Thus, in some centers, MRSA and VRE are the most prevalent resistant isolates, accounting for up to 20% and 50% of episodes, respectively [5] .
In patients with fever and neutropenia, recent guidelines do not recommend empiric therapy with antimicrobials, such as vancomycin, linezolid or daptomycin, but suggest early administration of these agents for patients with specific clinical indications or who are at risk of exposure to resistant bacteria [5] . These situations include patients with hemodynamic instability, suspected catheter-related infection, skin or soft tissue infection, pneumonia, previous infection or colonization with MRSA or VRE, or a hospital setting with high rates of resistant
Gram-positive pathogens [5] .
Vancomycin has been the mainstay of therapy for infections caused by resistant Gram-positive pathogens, such as MRSA, for several decades [6] . However, in patients with febrile neutropenia, it is associated with a delayed response and the development of resistant organisms [7] . Moreover, recent guidelines recommend using alternatives when the vancomycin minimum inhibitory concentration (MIC) of the infecting MRSA strain is increased [8, 9] . Indeed, many reports suggest a link between a higher vancomycin MIC of the infecting pathogen and a worse clinical outcome in patients with an MRSA infection [10] .
To improve the outcome of these vulnerable patients with neutropenia, daptomycin is an attractive agent because of its broad spectrum of activity and its bactericidal action. It is a lipopeptide antibiotic with rapid bactericidal activity against most clinically relevant
Gram-positive pathogens, including many antibiotic-resistant strains [11] [12] [13] . Daptomycin has not been formally evaluated in randomized trials in patients with neutropenia, but several case reports and abstracts have been published documenting its potential in this setting [14] [15] [16] . The retrospective analysis from the Cubicin Ò Outcome Registry and Experience (CORE) showed that daptomycin was effective and well tolerated in patients with neutropenia [17] . 
METHODS

Study Design and Data Collection
EU-CORE was a non-interventional, multicenter, retrospective, patient registry designed to collect real-world outcome in patients treated with daptomycin for Gram-positive infections.
Detailed EU-CORE methodology has been described elsewhere [18] . [20] . Clinical success was used to describe collectively patients with an outcome of cured or improved. Time to improvement was also recorded. Duration of treatment was measured as the number of inpatient and outpatient days during which the patient received daptomycin therapy, even if these were non-consecutive.
Adverse events (AEs) and serious AEs (SAEs) during daptomycin treatment, and 30-day follow-up period were assessed by the investigators. All deaths, AEs, and SAEs were recorded, regardless of their relation to daptomycin.
Statistical Analysis
The safety population included all eligible patients with at least one safety assessment and the efficacy population included all eligible patients for whom clinical outcome was assessed.
Given that this was a registry, no inferential analyses were conducted and no formal statistical methodology other than simple descriptive statistics was used. All analyses were considered to be explanatory.
Continuous variables were summarized as arithmetic mean, standard deviation, median, and range; categorical variables were summarized by absolute and relative frequencies.
Statistical analysis was performed using SAS version 9.3 (SAS Institute Inc., Cary, NC, USA).
RESULTS
Patient Demographic and Clinical
Characteristics
Of the 6075 patients enrolled in EU-CORE registry who had received at least one dose of daptomycin, 446 (7.3%) had an ANC B1000 cells/mm 3 at baseline or during daptomycin treatment; 50% (n = 223) had severe neutropenia (ANC B100 cells/mm 3 ). All patients selected for the present analysis were included in both safety and efficacy populations.
Baseline demographics and clinical characteristics of patients are summarized in Table 1 . Overall, 58.5% (n = 261) of patients were men and 26.2% (n = 117) had an age C65 years. The most common underlying diseases were hematologic malignancy (60.5%; n = 270), immunosuppressed state (39.7%; n = 177), and transplant (27.8%; n = 124). Results are given as n (%) unless otherwise indicated CrCl creatinine clearance a Missing data for n = 19 b More than one underlying disease could be reported c Lowest count at baseline or during daptomycin treatment
The most common primary infections were catheter-related bacteremia (30.5%; n = 136), non-catheter-related bacteremia (11.7%; n = 52), and complicated skin and soft tissue infection (cSSTI; 13.9%; n = 62) ( Table 2 ).
Microbiology
Results of cultures were available for 83.0%
(n = 370) of patients and were positive for 68.6% (n = 254) of them ( Table 3 ). The most common pathogens were coagulase-negative staphylococci (CoNS), which were identified in 43.7% (n = 111) of patients with positive culture and S. aureus in 18.9% (n = 48), with MRSA in 9.1% (n = 23). VRE were reported in 5.5% (n = 14) of patients.
Previous and Concomitant Antibiotic Therapy
Most patients (71.5%; n = 319) received other antibiotic therapy before daptomycin treatment; the most frequent antibiotics were penicillins (37.4%; n = 167), glycopeptides (32.5%; n = 145), and carbapenems (22.0%; n = 98) ( Table 1) . When daptomycin was administered with concomitant antibiotics (82.8%; n = 361), the most common antibiotics were carbapenems (51.2%; n = 185), penicillins (42.1%; n = 152), and aminoglycosides (19.9%; n = 72).
Daptomycin Prescribing Patterns
Daptomycin was used empirically (i.e., before culture results were known) in 56.1% (n = 250) of patients. Daptomycin was the first-line therapy for 27.5% (n = 121) of patients and second-line therapy for 72.5% (n = 319).
The most frequently prescribed doses of daptomycin were 6 mg/kg/day in 37.9%
(n = 169) of patients and 4 mg/kg/day in 25.8% (n = 115) of patients. Although we cannot exclude that some patients received suboptimal daptomycin treatment, 4 mg/ kg/day is the approved dose of daptomycin for cSSTI without bacteremia. A total of 16.0%
(n = 71) of patients received doses [6 and B10 mg/kg/day and 16.0% (n = 71) received doses [4 to \6 mg/kg/day; 3.4% (n = 15) of patients received \4 mg/kg/day and 1.1% (n = 5) of patients had no record of dose.
The median duration of daptomycin therapy was 10.0 (range 1-58) days. 
Clinical Outcomes
Clinical success (i.e., cured or improved) was reported for 77.1% (n = 344) of patients (46.2% were cured and 30.9% were improved). A total of 11.4% (n = 51) of patients were considered as clinical failures and 11.4% (n = 51) of patients were non-evaluable. Outcomes were comparable when analyzed by degree of neutropenia severity (Fig. 1) (n = 14) for endocarditis (Fig. 2) . The clinical success rates by infecting pathogen were high for CoNS (85.6%; n = 95) and S. aureus (77.1%; n = 39) (Fig. 3) . The clinical success rates were similar regardless of daptomycin dose or dose range. Higher clinical success rates were observed with increased duration of daptomycin therapy (Fig. 4) . The overall time to improvement was achieved within a median of 3 (range 1-30) days from initiation of daptomycin treatment.
Safety
AEs and SAEs, regardless of their relation to daptomycin, were reported in 19.3% (n = 86) and 15.2% (n = 68) of patients, respectively (Table 4) . Elevated serum creatine phosphokinase (CPK) was reported as an AE for one patient, but was considered to be unrelated to daptomycin by the investigator.
CPK was measured at baseline for 216 patients and most (89.8%) had normal values (B1 9 upper limit of normal; ULN). Three (1.4%) patients had elevated CPK levels ([10 9 ULN) at baseline. An elevation in CPK was observed in two patients (from B10 9 ULN at baseline to [10 9 ULN) during the study. There were no AEs of musculoskeletal and connective tissue disorders.
The total number of deaths was 50 (11.2%) during the study and were all unrelated to the study drug. However, despite decades of well-performed clinical trials, no single empirical therapeutic regimen for the initial treatment of febrile patients with neutropenia has emerged as being clearly superior to others [5, 21] . Thus, a recent Cochrane review concluded that the empirical routine addition of glycopeptides to anti-Gram-positive antibiotic treatment does not improve the outcomes of febrile patients with neutropenia and cancer [22] .
Both the increasing incidence and the array of antibiotic-resistant pathogens have become important challenges in the treatment of patients with neutropenia [23, 24] . Thus, both vancomycin and linezolid have limitations with respect to their use in patients with neutropenia. First, vancomycin is no longer a standard recommendation in initial antibiotic therapy for fever and neutropenia [5] . In addition, a series of studies showed a relation between a higher vancomycin MIC of the infecting pathogen and a worse clinical outcome of patients with an MRSA infection [10] . Second, although linezolid produced similar outcomes in febrile patients with neutropenia compared with vancomycin [25] , it is not bactericidal and might not be as Fig. 1 Clinical outcome by degree of neutropenia severity. Neutropenia severity was missing for n = 15 patients and neutropenia [6] . There were some case reports on the use of daptomycin subsequent to vancomycin-induced neutropenia [15] or the use of a combination of daptomycin and gentamicin in a neutropenic patient [14] . The CORE study registry reported a high clinical success rate (85%) in 186 patients with neutropenia and documented Gram-positive infections [17] . Daptomycin appears to be also suitable for outpatient therapy in cases of low-risk neutropenia [6] . In addition to its high effectiveness, our analysis showed that daptomycin was well interval with a once-daily regimen, reversible elevated serum CPK, and skeletal muscle toxicity had been reported [28] . In clinical trials with once-daily daptomycin, elevated CPK was reported in 7% of patients receiving 6 mg/kg/day, thus leading to study discontinuation in only 2.5% of patients.
Elevated CPK was not reported in patients receiving 4 mg/kg/day [29, 30] . Our safety data show that the impact of daptomycin was minimal on the serum CPK level because only one patient had elevated CPK during treatment (unrelated to daptomycin, according to the investigator) and there were no AEs related to musculoskeletal disorders. There were no new or unexpected safety findings.
There 
